Greehey CCRI News & Events Archive
Raushan Kurmasheva, PhD, Part of Dmitri Ivanov, PhD, CPRIT Grant Team “Identifying and Optimizing Small Molecules for Drug Development.
September 8, 2020SOURCE: UT Health San Antonio Newsroom “The following are the additional researchers and their awards: Dmitri Ivanov, PhD, associate professor of biochemistry and structural biology, will receive an Individual Investigator Research Award for Cancer in …
Nucleic Acids Research: “PCAT: an Integrated Portal for Genomic and Preclinical Testing Data of Pediatric Cancer Patient-Derived Xenograft Models” in Oxford Academic (multiple faculty and researchers)
September 8, 2020Juechen Yang, Qilin Li, Nighat Noureen (Greehey CCRI, Zheng Lab), Yanbing Fang, Raushan Kurmasheva (Greehey CCRI, Kurmasheva Lab), Peter J Houghton (Greehey CCRI, Houghton Lab), Xiaojing Wang (Greehey CCRI, Wang Lab), Siyuan Zheng (Greehey CCRI, Zheng …
Physician’s Weekly: PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.
August 20, 2020Although cancer is the leading cause of disease-related mortality in children, the relative rarity of pediatric cancers poses a significant challenge for developing novel therapeutics to further improve prognosis. Patient-derived xenograft (PDX) models …
Dr. Raushan Kurmasheva, JCM Guest Editor, invites you to submit research articles, review articles as well as short communications for the Special Issue “The Current Treatment of Childhood Cancer”, by November 30, 2020.
July 6, 2020
Clinical Cancer Research: Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts
June 1, 2020Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcom A. Smith, and Peter J. Houghton Abstract Purpose: Vincristine combined with camptothecin derivatives showe …
Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma (Kurmasheva Lab)
Paige Baldwin1, Rostislav Likhotvorik2, Nabeela Baig2, Jodie Cropper2, Ruth Carlson2, Raushan Kurmasheva2,3*† and Srinivas Sridhar1,4,5*† The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a me …
Springer: Prospective use of the single-mouse experimental design for the evaluation of PLX038A
January 11, 2020Samson Ghilu, Qilin Li, Shaun D. Fontaine, Daniel V. Santi, Raushan T. Kurmasheva, Siyuan Zheng & Peter J. Houghton Abstract Purpose Defining robust criteria for drug activity in preclinical studies allows for fewer animals per treatment group, and …
Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …
SCITECH EUROPA: Preclinical Drug Development for Childhood Cancers
December 2, 2019Cell Reports: Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
November 5, 2019Author links open overlay panelJo LynneRokita123 Komal S.Rathi23 Maria F.Cardenas4 Kristen A.Upton1 JoyJayaseelan4 Katherine L.Cross5 JacobPfeil6 Laura E.Egolf17 Gregory P.Way8 AlvinFarrel2 Nathan M.Kendsersky19 KhushbuPatel2 Krutika S.Gaon …